Atypical antipsychotics: new drugs, new challenges.
作者： M. Mathews , D. J Muzina
关键词: Glycemic 、 Weight gain 、 Hyperlipidemia 、 Cardiovascular risk factors 、 Type 2 Diabetes Mellitus 、 Psychiatry 、 Internal medicine 、 Antipsychotic 、 Medicine 、 Insulin resistance
摘要: Compared with the first-generation, or "typical" antipsychotic drugs, second-generation atypical antipsychotics cause fewer extrapyramidal (motor) problems, but they pose new challenges, as often contribute to metabolic disturbances such weight gain, hyperlipidemia, insulin resistance, and type 2 diabetes mellitus. Patients taking should be monitored for glycemic cardiovascular risk factors receive treatment problems arise.
sci-hub.se 参考文章(27)
Ereshefsky L, Pharmacokinetics and drug interactions: update for new antipsychotics. The Journal of Clinical Psychiatry. ,vol. 57, pp. 12- 25 ,(1996)
Seeman P, Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology. ,vol. 7, pp. 261- 284 ,(1992)
LA Chiodo, BS Bunney, Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons The Journal of Neuroscience. ,vol. 3, pp. 1607- 1619 ,(1983) , 10.1523/JNEUROSCI.03-08-01607.1983
H. E. Resnick, P. Valsania, J. B. Halter, X. Lin, Differential effects of BMI on diabetes risk among black and white Americans. Diabetes Care. ,vol. 21, pp. 1828- 1835 ,(1998) , 10.2337/DIACARE.21.11.1828
E. Wooltorton, Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials Canadian Medical Association Journal. ,vol. 170, pp. 1395- 1395 ,(2004) , 10.1503/CMAJ.1040539
Cindy P Lawler, Cassandra Prioleau, Mechelle M Lewis, Chun Mak, Dong Jiang, John A Schetz, Antonio M Gonzalez, David R Sibley, Richard B Mailman, Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology. ,vol. 20, pp. 612- 627 ,(1999) , 10.1016/S0893-133X(98)00099-2
John W. Newcomer, Second-Generation (Atypical) Antipsychotics and Metabolic Effects: A Comprehensive Literature Review. CNS Drugs. ,vol. 19, pp. 1- 93 ,(2005) , 10.2165/00023210-200519001-00001
D Daniel, Ziprasidone 80 mg/day and 160 mg/day in the Acute Exacerbation of Schizophrenia and Schizoaffective Disorder: A 6-Week Placebo-Controlled Trial Neuropsychopharmacology. ,vol. 20, pp. 491- 505 ,(1999) , 10.1016/S0893-133X(98)00090-6
Gerard Boehm, Judith A Racoosin, Thomas P Laughren, Russell Katz, None, Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes Response to consensus statement Diabetes Care. ,vol. 27, pp. 2088- 2089 ,(2004) , 10.2337/DIACARE.27.8.2088-A
Gary E Duncan, Brian B Sheitman, Jeffery A Lieberman, An integrated view of pathophysiological models of schizophrenia. Brain Research Reviews. ,vol. 29, pp. 250- 264 ,(1999) , 10.1016/S0165-0173(99)00002-8